Two-Drug combo shows promise in keeping head and neck cancer at bay
Disease control
Ongoing
This phase 2 trial is testing whether adding lenvatinib to pembrolizumab (Keytruda) after standard chemoradiation can help prevent head and neck cancer from coming back. About 50 patients with advanced, PD-L1 positive cancer will receive either the combination or pembrolizumab al…
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC